Drug
Voglibose clinical trials
Also written Basen.
- studies test it
- 9
- open now
- 1
- in phase 3
- 4
- first study started
- 2005
Keep track of what changes. Save the voglibose studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 4
- Phase 4
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 3
Takeda (4) · Novartis Pharmaceuticals (1) · Merck Sharp & Dohme LLC (1) · University of Zambia (1) · National Cerebral and Cardiovascular Center, Japan (1) · Ministry of Science and Technology of the People´s Republic of China (1)
Often tested with
Tested in the same studies.
Alogliptin (2) · Vildagliptin (1) · Sitagliptin (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses voglibose is read from its arms, and is right about nine times in ten.
Testing it · 9
- Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM PatientsNot yet recruitingPhase 3University of ZambiaNCT05688332Written as Voglibose + Metformin
- Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 DiabetesCompletedPhase 4Novartis PharmaceuticalsNCT01309698Written as Voglibose
- Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 DiabetesCompletedPhase 4TakedaNCT02049814Written as Voglibose
- Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGTTerminatedNot applicableNational Cerebral and Cardiovascular Center, JapanNCT00212017Written as voglibose
- MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)CompletedPhase 3Merck Sharp & Dohme LLCNCT00837577Written as Voglibose
- Postmarketing Clinical Study on AO-128CompletedPhase 4TakedaNCT02287402Written as AO-128
- Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanCompletedPhase 2/3TakedaNCT01263509Written as Alogliptin and voglibose
- Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanCompletedPhase 2/3TakedaNCT01263483Written as Alogliptin and voglibose
- Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.Status unknownNot applicableMinistry of Science and Technology of the People´s Republic of ChinaNCT00724542Written as Voglibose tablets
As the comparator · 7 — what is tested is compared with voglibose
- A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00411554Written as Comparator: voglibose
- Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes MellitusStatus unknownPhase 4Post Graduate Institute of Medical Education and Research, ChandigarhNCT02097342Written as Voglibose
- Glucose Reduction by Early Acarbose Treatment in Basal InsulinCompletedPhase 4BayerNCT00970528Written as Voglibose (Basen)
- Japanese P III vs Voglibose and PlaceboCompletedPhase 3Boehringer IngelheimNCT00654381Written as voglibose
- Glufast On Insulin Glargine Trial in Type 2 DMCompletedPhase 4JW PharmaceuticalNCT00663884Written as Voglibose
- Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in JapanCompletedPhase 2TakedaNCT01263496Written as Voglibose
- Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in JapanCompletedPhase 2TakedaNCT01263470Written as Voglibose
Codes
What other systems call voglibose · ClinicalTrials.gg INT003945
- MeSH (NLM) C102817vogliboseConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S77P977AG8VOGLIBOSEConfirmed FDA, NLM, Wikidata
- Wikidata Q7939403vogliboseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95221VogliboseOne source FDA
- DrugBank DB04878One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C102817 | voglibose | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S77P977AG8 | VOGLIBOSE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7939403 | voglibose | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95221 | Voglibose | One source FDA |
| DrugBank | DB04878 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.